Flomics participates in LUMINA, a Eurostars-funded project to detect lung cancer recurrence through liquid biopsy and artificial intelligence
Barcelona – June 09, 2026 –
Flomics Biotech is leading an international consortium that has been selected for funding by the Eureka Eurostars programme. The LUMINA project (Lung Adenocarcinoma Minimal Residual Disease Detection using an Integrated cfDNA and cfRNA Approach), which started on the first of June 2025 and with a duration of 3 years, aims to develop an innovative platform for the non-invasive detection of minimal residual disease (MRD) in lung cancer patients using multi-omic biomarkers and artificial intelligence algorithms.
Minimal residual disease remains one of the most pressing challenges in oncology, particularly in lung cancer, where up to 60% of patients treated with curative intent experience relapse. LUMINA seeks to address this unmet need by analysing blood and urine samples—through liquid biopsy—and integrating RNA and DNA circulating biomarkers with advanced predictive models. This approach will enable early identification of disease progression, even before it becomes clinically or radiologically evident, allowing for timely therapeutic decisions and improving patient outcomes.
Flomics brings its expertise in total RNA analysis for liquid biopsy applications, a field in which the company has positioned itself as a leader in recent years. Its technology enables the detection of complex molecular signatures that complement DNA-based analyses, ultimately enhancing the platform’s sensitivity and specificity. Combined with machine learning tools developed by the consortium partners, this multi-omic approach could redefine clinical standards for post-treatment monitoring.
The consortium also includes Uppsala University, a European leader in biomedical research and biobanking, Methylomics, a Dutch company specialised in methylation-based cancer diagnostics, You2Yourself, a Dutch company developing cancer detection tests using microRNA profiling in blood and urine, and Oncodia AB, a Swedish company specialized in the development of CE/IVD-certified molecular diagnostic products for cancer. This transnational collaboration brings together complementary expertise to cover all phases of the project—from biomarker discovery to clinical implementation.
With this new milestone, Flomics strengthens its position as a key player in the development of advanced RNA-based diagnostics and reaffirms its commitment to precision medicine and international collaboration.
Las actividades de Flomics en LUMINA cuentan con una subvención de 619 k€ subvencionada por el CDTI, y el proyecto ha sido apoyado por el Ministerio de Ciencia, Innovación y Universidades de España. Este proyecto ha recibido financiación del Programa Eurostars-3 con cofinanciación de CDTI y del Programa Marco de Investigación e Innovación «Horizonte Europa» de la Unión Europea.
